General Information of Drug (ID: DML38VU)

Drug Name
PF-446687 Drug Info
Synonyms PF-00446687; PF-2336652
Indication
Disease Entry ICD 11 Status REF
Female sexual arousal dysfunction HA01.1 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DML38VU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methylnaltrexone bromide DMZTGN2 Opioid-induced constipation DB32.1 Approved [3]
Bremelanotide DM20LIM Hypoactive sexual desire dysfunction HA00 Approved [4]
Setmelanotide DMPVRN9 Obesity 5B81 Approved [5]
Amylin DMWDEN0 N. A. N. A. Phase 4 [6]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [3]
PMX-53 DMZUAJ4 Atopic dermatitis EA80 Phase 2 [7]
AP-1030 DMBGA35 Metabolic disorder 5C50-5D2Z Phase 1/2 [8]
PF-07258669 DM3CJ5N Malnutrition 5B50-5B71 Phase 1 [9]
PT-14 DMYM9JL Erectile dysfunction HA01.1 Discontinued in Phase 2 [10]
Melanotetan II DMYK8MV Obesity 5B81 Preclinical [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Melanocortin receptor 4 (MC4R) TTD0CIQ MC4R_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00862888) Study to Investigate Effect of a New Drug (PF-00446687) in Males Suffering From Erectile Dysfunction. U.S. National Institutes of Health.
2 Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
3 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6 Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
7 Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
8 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9 Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss. J Med Chem. 2023 Mar 9;66(5):3195-3211.
10 The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51.